Investment Thesis
Exact Sciences demonstrates strong operational fundamentals with excellent gross margins (69.7%), positive free cash flow generation ($356.8M), and healthy balance sheet liquidity, but is currently unprofitable at the operating and net income levels despite stable revenue. The company's ability to convert high-margin revenue into sustainable profitability remains the critical question, though positive FCF and improving EPS trends suggest operational momentum.
Strengths
- Exceptional gross margin of 69.7% indicates strong pricing power and operational efficiency in core laboratory business
- Robust free cash flow of $356.8M with 11.0% FCF margin demonstrates ability to generate cash despite accounting losses
- Strong balance sheet with 2.43x current ratio, minimal debt burden (0.02x debt-to-equity), and $956M cash position providing financial flexibility
- Significant improvement in diluted EPS (-1.10 vs prior year performance) showing operational leverage and path toward profitability
- Active insider participation with 28 Form 4 filings in last 90 days suggesting management confidence
Risks
- Negative operating margin (-6.4%) and net margin (-6.4%) indicate company is currently unprofitable despite generating revenue and positive cash flow
- Stagnant revenue growth (0.0% YoY) raises concerns about market saturation, competitive pressures, or execution challenges in core business
- Negative ROE (-8.7%) and ROA (-3.5%) signal inefficient capital deployment and value destruction from shareholder equity base
- Large gap between operating cash flow and net income suggests reliance on working capital management rather than sustainable profitability
- Negative interest coverage ratio (-6.3x) indicates insufficient operating earnings to service debt obligations
Key Metrics to Watch
- Operating margin trajectory toward profitability as leverage on fixed cost base improves
- Revenue growth acceleration as key inflection point given current 0% YoY stagnation
- Free cash flow sustainability and conversion rate as percentage of revenue
- SG&A expense reduction and operating expense management to drive toward EBITDA positivity
- Gross margin maintenance above 65% as pricing power indicator in competitive markets
Financial Metrics
Revenue
3.2B
Net Income
-207.9M
EPS (Diluted)
$-1.10
Free Cash Flow
356.8M
Total Assets
5.9B
Cash
956.0M
Profitability Ratios
Gross Margin
69.7%
Operating Margin
-6.4%
Net Margin
-6.4%
ROE
-8.7%
ROA
-3.5%
FCF Margin
11.0%
Balance Sheet & Liquidity
Current Ratio
2.43x
Quick Ratio
2.17x
Debt/Equity
0.02x
Debt/Assets
59.0%
Interest Coverage
-6.28x
Long-term Debt
50.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T16:16:12.514618 |
Data as of: 2025-12-31 |
Powered by Claude AI